



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

**Public Declaration of Interests and Confidentiality Undertaking of
European Medicines Agency (EMA),
Scientific Committee members and experts**

Public declaration of interests

I, **Daniela Cianci**

Organisation/Company: Medicines Evaluation Board

Country: Netherlands

do hereby declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below:

2.1 Employment

No interest declared

2.2 Consultancy

No interest declared

2.3 Strategic advisory role

No interest declared

2.4 Financial interests

No interest declared

2.5 Principal investigator

No interest declared

2.6 Investigator

No Interest Declared

2.7 Grant / Funding to organisation /institution

Company	Subject Matter
Daiichi-Sankyo	Quizartinib AC220-A-U202 trial

2.8 Close family member interest

No interest declared

2.9 Any other interests or facts

I also work at the Department of Biostatistics and Research Support in the University Medical Center Utrecht (UMCU) as Assistant Professor with focus on design, methodology and analysis of clinical trials and in the research group of Michel Zwaan, principal investigator for Drug Development/Experimental Therapeutics and head of the Trial and Data Center at the Princess Máxima Center in Utrecht. At the Trial and Data Center of PMC I am involved in the design and analysis of phase I-II trial in pediatric oncology. Currently I am working on the Quizartinib AC220-A-U202 trial in which Daiichi-Sankyo is involved and on Heam Smart (not funded yet).

A complete list of the trials ongoing at PMC, together with products and companies involved, is provided below:

Study	Product	Company
Afatinib 1200.120	Afatinib	Boehringer Ingelheim
AMoRe2017	Azacitidine	Celgene
Beacon	Bevacizumab	Roche
BIANCA	Tisagenlecleucel	Novartis
Biomede	Erlotinib, Everolimus, Dasatinib	Roche, Novartis, BMS
Blina Infant	Blinatumomab	Amgen
Blinatumomab 20120215	Blinatumomab	Amgen
Bosutinib	Bosutinib	Pfizer
CA180-226	Dasatinib	BMS
CA209-744	Nivolumab, Brentuximab	BMS
CA209-908	Nivolumab, Ipilimumab	BMS
CASSIOPEIA	Tisagenlecleucel	Novartis
CETB Revolade	Eltrombopag (ETB115)	Novartis
Crisp	Crizotinib	Pfizer
Dabrafenib	Dabrafenib, Trametinib	Novartis
Daratumumab ALL2005	Daratumumab	Janssen
Durvalumab	Durvalumab, Tremelimumab	AstraZeneca
Epizyme EZH102	Tazemetostat (EPZ-6438)	Epizyme
Esmart	Ribociclib, AZD1775, Olaparib, AZD214,	AstraZeneca, Novartis, BMS
Ibrutinib Sparkle	Ibrutinib	Janssen
INFORM2	Nivolumab, Entinostat	BMS, Syndax
Inotuzumab	Inotuzumab	Pfizer
Isatuximab ACT15378	Isatuximab	Sanofi
LOXO	Larotrectinib (LOXO-101)	Bayer
M13-833	Venetoclax	Abbvie
MK0517-045	Fosaprepitant	Merck Sharp & Dohme
NiCord III	NiCord®	Gamida Cell
PARC	PEG- BCT-100	University of Birmingham
PCYC-Ibrutinib cGvHD		
PCYC-1146-IM	Ibrutinib (PCI-32765)	Pharmacyclics
Ponatinib	Ponatinib	Incyte
Quizartinib AC220-A-U202	Quizartinib	Daiichi-Sankyo
Vidaza	Azacitidine	Celgene
ZUMA-4	KTE-C19	Kite Pharma

CONFIDENTIALITY UNDERTAKING

In view of the following definitions:

"EMA Activities" encompass any meeting (including meeting preparation and follow-up, associated discussion or any other related activity) of the European Medicines Agency's Management Board, Committees, Working Parties, Expert Groups, or any other such meeting; work as an expert on assessments; work as an expert on guidance development.

"Confidential Information" means all information, facts, data and any other matters of which I acquire knowledge, either directly or indirectly, as a result of my EMA Activities.

"Confidential Documents" mean all drafts, preparatory information, documents and any other material, together with any information contained therein, to which I have access, either directly or indirectly, as a result of my participation in EMA Activities. Furthermore, any records or notes made by me relating to Confidential Information or Confidential Documents shall be treated as Confidential Documents.

I understand that I may be invited to participate either directly or indirectly in certain EMA activities and hereby undertake:

- To treat all Confidential Information and Confidential Documents under conditions of strict confidentiality.
- Not to disclose (or authorise any other person to disclose) in any way to any third party any Confidential Information or Confidential Document.
- Not to use (or authorise any other person to use) any Confidential Information or Confidential Document other than for the purposes of my work in connection with EMA activities.
- To dispose of Confidential Documents as confidential material as soon as I have no further use for them.

This undertaking shall not be limited in time, but shall not apply to any document or information that I can reasonably prove was known to me before the date of this undertaking or which becomes public knowledge other than as a result of a breach of any of the above undertakings.

I confirm the information declared on this form is accurate to the best of my knowledge and I acknowledge that my information will be stored electronically and published on the EMA website.

Full Name:	Daniela Cianci
Date:	2020-05-27

For Definitions of activities etc, refer to Policy on Handling of Conflicts of Interest / Electronic DOI template